Company Profile: Krystal Biotech, Inc.
Background
Krystal Biotech, Inc. is a commercial-stage biotechnology company headquartered in Pittsburgh, Pennsylvania. Established in 2016, the company specializes in the discovery, development, and commercialization of genetic medicines aimed at treating diseases with high unmet medical needs. Its flagship product, VYJUVEK (beremagene geperpavec-svdt), is the first FDA-approved redosable gene therapy for the treatment of dystrophic epidermolysis bullosa (DEB), a rare and debilitating skin disorder. Krystal Biotech's mission is to develop transformative gene therapies that significantly improve the lives of patients affected by serious skin diseases.
Key Strategic Focus
Krystal Biotech's strategic focus centers on leveraging its proprietary gene therapy platform to address rare and serious skin diseases. The company's core objectives include:
- Advancing Gene Therapy Treatments: Developing innovative therapies that offer durable and effective solutions for patients with high unmet medical needs.
- Expanding Global Reach: Commercializing its products in key markets, including the United States, Europe, and Japan, to maximize patient access.
- Broadening Pipeline Development: Advancing a diverse pipeline of gene therapies targeting various dermatological conditions.
Krystal Biotech utilizes its proprietary gene delivery platform based on engineered herpes simplex virus-1 (HSV-1) vectors, enabling efficient and non-invasive delivery of therapeutic genes to target cells. This platform is central to the company's approach in developing treatments for conditions such as DEB, cystic fibrosis, and other genetic skin disorders.
Financials and Funding
As of September 30, 2025, Krystal Biotech reported a net product revenue of $282.0 million for the nine months ending on that date, a significant increase from $199.4 million in the same period in 2024. The company's gross margin for the third quarter of 2025 stood at 96%, reflecting strong operational efficiency. Krystal Biotech ended the quarter with a robust balance sheet, holding $864.2 million in cash, cash equivalents, and investments, providing substantial financial flexibility for ongoing and future initiatives.
Pipeline Development
Krystal Biotech's pipeline includes several promising gene therapy candidates:
- KB407: In Phase 1 clinical trials for the treatment of cystic fibrosis.
- KB408: In Phase 1 clinical trials targeting Alpha-1 antitrypsin deficiency.
- KB105: In Phase 1/2 clinical trials for deficient autosomal recessive congenital ichthyosis.
- KB104: In development for Netherton syndrome.
- KB707: In Phase 1/2 clinical trials for anti-PD-1 relapsed/refractory conditions.
- KB301: In Phase 2 clinical trials for aesthetic skin conditions and in an open-label study with ophthalmic B-VEC for ocular complications of DEB.
Technological Platform and Innovation
Krystal Biotech's proprietary gene delivery platform, known as STAR-D, utilizes engineered HSV-1 vectors to deliver therapeutic genes efficiently to target cells. This platform allows for non-invasive or minimally invasive administration routes, such as topical application, enhancing patient convenience and compliance. The FDA granted a Platform Technology Designation to the HSV-1 vector, recognizing its potential to streamline the development and approval of future gene therapies.
Leadership Team
Krystal Biotech is led by a team of experienced professionals:
- Krish S. Krishnan: Chairman and CEO.
- Suma M. Krishnan: President, Research and Development.
- Jessica Hagler: Chief Financial Officer.
- Casey Terrell: Chief Marketing Officer.
The leadership team is committed to advancing the company's mission through scientific innovation, operational excellence, and a patient-centric approach.
Strategic Collaborations and Partnerships
Krystal Biotech has established strategic collaborations to enhance its research and development capabilities and expand its market reach. Notably, the company has secured over 615 reimbursement approvals for VYJUVEK in the U.S., facilitating patient access to its therapies. Internationally, Krystal Biotech launched VYJUVEK in Germany in the third quarter of 2025 and began commercial operations in France and Japan in the fourth quarter of 2025, demonstrating its commitment to global expansion.
Operational Insights
Krystal Biotech's operational strategy emphasizes the efficient development and commercialization of gene therapies. The company's proprietary platform technology and strong financial position enable it to advance a diverse pipeline targeting various dermatological conditions. Krystal Biotech's focus on patient-centric solutions and global market expansion positions it as a leader in the gene therapy sector.
Strategic Opportunities and Future Directions
Krystal Biotech aims to leverage its proprietary gene delivery platform to develop treatments for a broader range of dermatological conditions. The company's strong financial position and successful commercialization of VYJUVEK provide a solid foundation for future growth and innovation. Krystal Biotech's strategic roadmap includes expanding its global footprint, advancing its pipeline, and enhancing patient access to its therapies.
Competitor Profile
Krystal Biotech operates in the competitive gene therapy sector, focusing on rare and serious skin diseases. Key competitors include:
- AVROBIO: A biotechnology company specializing in gene therapies for rare diseases.
- Erytech: Focuses on developing red blood cell-based therapies for rare cancers and orphan diseases.
- Spark Therapeutics: Develops gene therapies for genetic diseases, including hemophilia and inherited retinal diseases.
Stock Market Information for Krystal Biotech Inc (KRYS)
- Krystal Biotech Inc is an equity in the USA market.
- The price is $246.69 currently with a change of $5.89 (0.02%) from the previous close.
- The latest open price was $241.43 and the intraday volume is 29,150.
- The intraday high is $247.55 and the intraday low is $241.52.
- The latest trade time is Monday, December 22, 07:45:49 PST.
